Safety of thalidomide in newly diagnosed elderly myeloma patients: A meta-analysis of data from individual patients in six randomized trials

Haematologica

Volumn 98, Issue 1, 2013, Pages 87-94

  Palumbo, Antonio ^a   Waage, Anders ^b   Hulin, Cyrille ^c   Beksac, Meral ^d   Zweegman, Sonja ^e   Gay, Francesca ^a   Gimsing, Peter ^f   Leleu, Xavier ^g   Wijermans, Pierre ^h   Sucak, Gülsan ⁱ   Pezzatti, Sara ^j   Juliusson, Gunnar ^k   Pégourié, Brigitte ^l   Schaafsma, Martijn ^m   Galli, Monica ⁿ   Turesson, Ingemar ^o   Kolb, Brigitte ^p   van der Holt, Bronno ^q   Baldi, Ileana ^r   Rolke, Jürgen ^s   Ciccone, Giovannino ^t   Wetterwald, Marc ^u   Lokhorst, Henk ^v   Boccadoro, Mario ^a   Rodon, Philippe ^w   Sonneveld, Pieter ^q   more..

^a UNIVERSITY OF TURIN   (Italy)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c CHU NANCY BRABOIS   (France)

^d ANKARA UNIVERSITY   (Turkey)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h HAGA HOSPITAL   (Netherlands)

ⁱ GAZI UNIVERSITY   (Turkey)

^j SAN GERARDO HOSPITAL   (Italy)

^k LUND UNIVERSITY   (Sweden)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m MEDISCH SPECTRUM TWENTE   (Netherlands)

ⁿ OSPEDALI RIUNITI   (Italy)

^o LUND UNIVERSITY HOSPITAL   (Sweden)

^p REIMS UNIVERSITY HOSPITAL   (France)

^q ERASMUS MEDICAL CENTER   (Netherlands)

^r UNIVERSITY OF PADOVA   (Italy)

^s AOU San Giovannni Battista e CPO Piemonte ^*  (Norway)

^t AOU San Giovannni Battista e CPO Piemonte   (Italy)

^u Dunkerque Hospital   (France)

^v UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^w CENTRE HOSPITALIER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ARTICLE; DEEP VEIN THROMBOSIS; DRUG SAFETY; GASTROINTESTINAL DISEASE; GENDER; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LUNG EMBOLISM; META ANALYSIS; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; THALIDOMIDE;

EID: 84872055497     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.067058     Document Type: Article

References (28)

1. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21): 1565-71.
2. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825-31.
3. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112(8):3107-14.
4. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reducedintensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-18.
5. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664-70.
6. Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol. 2010;28 (19):3160-6.
7. Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116(9): 1405-12.
8. Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2010;86(1):16-22.
9. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118 (5):1239-47.
10. Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, et al. Thalidomide-dexamethasone compared with melphalanprednisolone in elderly patients with multiple myeloma. Blood. 2009;113(15):3435-42.
11. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an openlabel randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
12. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF Sr, Whittenberger BF, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010;116(26):5838-41.
13. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23): 4745-53.
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
15. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20.
16. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54.
17. National Cancer Institute. National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0. 9 August. http:// ctep.cancer.gov/protocolDevelopment/elec tronic_applications/ctc.htm#ctc_30
18. Katsahian S, Resche-Rigon M, Chevret S, Porcher R. Analysing multicentre competing risk data with mixed proportional hazards model for the subdistribution. Stat Med. 2006;25(24):4267-78.
19. Clayton D, Cuzick J. Multivariate generalisations of the proportional hazards model (with discussion). Journal of the Royal Statistical Society, Series A 1985;148:82-117.
20. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan and prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol. 1998;16(12):3832-42.
21. Facon T, Mary JY, Pégourie B, Attal M, Renaud M, Sadoun A, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2006;107(4):1292-8.
22. Palumbo A, Facon T, Sonneveld P, Bladè J, Offidani M, Gay F, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968-77.
23. Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111(8):4039-47.
24. Vestal RE. Aging and pharmacology. Cancer. 1997;80(7):1302-10.
25. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med. 1990;6(2):257-67.
26. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61(3):331-9.
27. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-60.
28. Liberati A. Need to realign patient-oriented and commercial and academic research. Lancet. 2011;378(9805):1777-8.